Dr. Reddy's Q3 Profitability Declines 14% Amid Biosimilar Setbacks and Lower Lenalidomide Sales

summarizeSummary

Dr. Reddy's Laboratories reported a significant decline in Q3 FY26 profitability, with diluted EPS falling 14% year-over-year, primarily due to lower Lenalidomide sales, price erosion, and one-time provisions, alongside receiving two Complete Response Letters (CRLs) from the USFDA for key biosimilar candidates.

check_boxKey Events

• Profitability Decline

  Q3 FY26 diluted EPS decreased by 14% year-over-year to ₹14.52, with profit before tax falling 18% and profit after tax declining 14%.

• Revenue Growth Impacted by North America

  Consolidated revenues grew 4.4% year-over-year to ₹87.3 billion, but declined 0.9% quarter-over-quarter, impacted by a 12% drop in North America generics revenue due to lower Lenalidomide sales and price erosion.

• Biosimilar Regulatory Setbacks

  Received Complete Response Letters (CRLs) from the USFDA for both denosumab and rituximab biosimilar candidates, citing facility inspection observations.

• Strategic Collaboration Announced

  Entered a strategic collaboration with Immutep for an immunotherapy oncology drug, Eftilagimod Alfa, with an upfront payment of US$20 million and potential milestones up to US$349.5 million.

auto_awesomeAnalysis

Dr. Reddy's Q3 FY26 results indicate a challenging quarter marked by a notable decline in profitability and significant regulatory hurdles for its biosimilar pipeline. The 14% year-over-year drop in diluted EPS, coupled with an 18% fall in profit before tax, signals underlying pressures on the company's core business. The North American generics segment, a key market, experienced a substantial revenue decline due to reduced Lenalidomide sales and increased price erosion, highlighting competitive pressures. Furthermore, the receipt of two Complete Response Letters from the USFDA for critical biosimilar candidates (denosumab and rituximab) represents a material setback, delaying potential market entry and future revenue streams. While the strategic collaboration with Immutep and positive USFDA inspection outcomes for other facilities offer some positive developments, they are overshadowed by the financial underperformance and the regulatory delays for high-value biosimilars. Investors should monitor the company's progress in addressing the USFDA observations and its ability to mitigate ongoing pricing pressures and one-time charges.